M
Martin A. Graham
Publications - 5
Citations - 380
Martin A. Graham is an academic researcher. The author has contributed to research in topics: XIAP & Cancer. The author has an hindex of 3, co-authored 5 publications receiving 334 citations.
Papers
More filters
Journal ArticleDOI
Birinapant (TL32711), a bivalent SMAC mimetic, targets TRAF2-associated cIAPs, abrogates TNF-induced NF-κB activation, and is active in patient-derived xenograft models.
Christopher A. Benetatos,Yasuhiro Mitsuuchi,Jennifer M. Burns,Eric M. Neiman,Stephen M. Condon,Guangyao Yu,Martin E. Seipel,Gurpreet S. Kapoor,Matthew G. LaPorte,Susan R. Rippin,Yijun Deng,Mukta S. Hendi,Pavan K. Tirunahari,Yu-Hua Lee,Thomas Haimowitz,Matthew D Alexander,Martin A. Graham,David E. Weng,Yigong Shi,Mark A. McKinlay,Srinivas K. Chunduru +20 more
TL;DR: The preclinical characterization of birinapant (TL32711) is reported, a bivalent SMAC-mimetic compound currently in clinical trials for the treatment of cancer, which supports the therapeutic combination of birInapant with multiple chemotherapies, in particular, those therapies that can induce TNF secretion.
Journal ArticleDOI
Birinapant, a Smac-Mimetic with Improved Tolerability for the Treatment of Solid Tumors and Hematological Malignancies
Stephen M. Condon,Yasuhiro Mitsuuchi,Yijun Deng,Matthew G. LaPorte,Susan R. Rippin,Thomas Haimowitz,Matthew D Alexander,Pavan Tirunahari Kumar,Mukta S. Hendi,Yu Hua Lee,Christopher A. Benetatos,Guangyao Yu,Gurpreet S. Kapoor,Eric M. Neiman,Martin E. Seipel,Jennifer M. Burns,Martin A. Graham,Mark A. McKinlay,Xiaochun Li,Jiawei Wang,Yigong Shi,Rebecca Feltham,Bodhi Bettjeman,Mathew H. Cumming,James E Vince,Nufail Khan,John Silke,John Silke,Catherine L. Day,Srinivas K. Chunduru +29 more
TL;DR: Improved tolerability of 1 was associated with decreased potency against cIAP2 and affinity for XIAP BIR3 and decreased ability to inhibit XIAP-dependent signaling pathways, and this improved tolerability has allowed 1 to proceed into clinical studies.
Journal ArticleDOI
A Phase I Study of the SMAC-Mimetic Birinapant in Adults with Refractory Solid Tumors or Lymphoma.
Ravi K. Amaravadi,Russell J. Schilder,Lainie P. Martin,Myron J. Levin,Martin A. Graham,David E. Weng,Alex A. Adjei +6 more
TL;DR: A first-in-human trial designed to determine the maximum tolerated dose (MTD), safety, and pharmacokinetics/pharmacodynamics (PK/PD) of birinapant, a novel SMAC mimetic, found it well tolerated with an MTD of 47 mg/m2 and exhibited favorable PK and PD properties.
Proceedings ArticleDOI
Abstract B163: Pharmacokinetic analysis and preclinical evaluation of the SMAC mimetic TL32711 in an orthotopic human breast tumor xenograft model
Mitchell M. Moore,Vanessa A. Estrada,Francis E. Nieves,Jennifer M. Burns,Yasuhiro Mitsuuchi,Srinivas K. Chunduru,Martin A. Graham,Mark A. McKinlay,Anthony W. Tolcher,Michael J. Wick +9 more
TL;DR: TL32711 is a SMAC mimetic which has demonstrated potent and selective activity in several human tumor cell lines as well as in vitro inhibition of IAP target proteins and PK/PD analysis demonstrated dose and time dependent target inhibition in vivo and decreased half life in tumor tissue.
Proceedings ArticleDOI
Abstract A225: Dose scheduling and efficacy analysis of the SMAC mimetic TL32711 in primary melanoma tumor xenotransplant models.
Jennifer M. Burns,Yasuhiro Mitsuuchi,Srinivas K. Chunduru,Francis E. Nieves,Michael J. Wick,Anthony W. Tolcher,Kyriakos P. Papadopoulos,Martin A. Graham,Mark A. McKinlay +8 more
TL;DR: Evaluated the efficacy of TL32711 as a single agent in primary human melanoma tumor xenograft models and assessed the efficacy and tolerability ofTL32711 in combination with carboplatin and paclitaxel to determine if a biweekly dosing schedule is more effective than weekly administration.